Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

163.20 -1.62 (-0.98%)
Streaming Delayed Price Updated: 11:22 AM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,119,455
Open 164.20
Bid (Size) 163.18 (3)
Ask (Size) 163.22 (2)
Prev. Close 164.82
Today's Range 162.71 - 165.10
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 2.92%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
How To Earn $500 A Month From Johnson & Johnson Stock
Johnson & Johnson offers an annual dividend yield of 3.01%. How can investors exploit its dividend yield to pocket a regular $500 monthly? 
Via Benzinga

Performance

YTD
+2.02%
+2.02%
1 Month
+2.08%
+2.08%
3 Month
+12.23%
+12.23%
6 Month
+1.30%
+1.30%
1 Year
-0.23%
-0.23%

More News

Read More
Metals in Tampons: FDA Initiates New Safety Measures and Testing
Via Benzinga
Exposures Product Safety
Sony Music-Universal Music JV Hits Johnson & Johnson With Copyright Lawsuit Over Unlicensed Music Use Covering 80 Videos
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions
Via Benzinga
Analyzing NYSE:JNJ's Dividend Potential.
Via Chartmill
3 Safe Stocks with Safe Dividends for Your Portfolio
Via MarketBeat
Topics Economy
Exposures Economy
Is Hims & Hers Health the Next Teladoc?
Via The Motley Fool
Exposures COVID-19
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
Via The Motley Fool
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Via Benzinga
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
Via Benzinga
Dell, CoStar, PayPal And A Major Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Raises Talc Settlement Offer to $9B, Moves Closer to Settlement Victory
Via Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem
Via The Motley Fool
Court Orders Johnson & Johnson To Compensate Auris Health Shareholders $1B
Via Benzinga
3 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
Critical Insights From Johnson & Johnson Analyst Ratings: What You Need To Know
Via Benzinga
Is Johnson & Johnson the Best Dividend Stock for You?
Via The Motley Fool
Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
Via The Motley Fool
Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps
Via Benzinga
Topics Lawsuit
Exposures Financial Legal Product Safety
Elliott Wave Technical Analysis: Johnson & Johnson - Friday, Aug. 30
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.